S. Neuhoff

发表

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

M. Jamei, X. Chu, K. Hillgren, 2013, Drug Metabolism and Disposition.

A Mechanistic Framework for In Vitro–In Vivo Extrapolation of Liver Membrane Transporters: Prediction of Drug–Drug Interaction Between Rosuvastatin and Cyclosporine

M. Jamei, F. Bajot, A. Rostami-Hodjegan, 2013, Clinical Pharmacokinetics.

Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis

S. Neuhoff, H. Crewe, H. Burt, 2016, Drug Metabolism and Disposition.

pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers.

Ismael Zamora, Per Artursson, Sibylle Neuhoff, 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption.

A Rostami-Hodjegan, G. Warhurst, A. Rostami-Hodjegan, 2013, Biopharmaceutics & drug disposition.

A Laboratory-Specific Scaling Factor to Predict the In Vivo Human Clearance of Aldehyde Oxidase Substrates

S. Neuhoff, V. Pilla Reddy, I. Gardner, 2020, Drug Metabolism and Disposition.

Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates

Shiew-Mei Huang, Ping Zhao, Lei Zhang, 2018, Clinical pharmacology and therapeutics.

Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs

Masoud Jamei, David B. Turner, Sibylle Neuhoff, 2017, The AAPS Journal.

Characterization of Contributing Factors to Variability in Morphine Clearance Through PBPK Modeling Implemented With OCT1 Transporter

A. Vinks, S. Neuhoff, T. Fukuda, 2016, CPT: pharmacometrics & systems pharmacology.

Application of a Physiologically Based Pharmacokinetic Model to Predict OATP1B1-Related Variability in Pharmacodynamics of Rosuvastatin

A Rostami-Hodjegan, M Jamei, M. Jamei, 2014, CPT: pharmacometrics & systems pharmacology.

Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux.

Masoud Jamei, David B Turner, Amin Rostami-Hodjegan, 2013, Journal of pharmaceutical sciences.

Proteomic Quantification of Human Blood-Brain Barrier SLC and ABC Transporters in Healthy Individuals and Dementia Patients.

A. Rostami-Hodjegan, B. Achour, S. Neuhoff, 2019, Molecular pharmaceutics.

Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.

W. Yue, K. Ding, S. Neuhoff, 2017, Journal of Pharmacy and Science.

Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling

A. Rostami-Hodjegan, S. Neuhoff, K. Doki, 2019, CPT: pharmacometrics & systems pharmacology.

Application of proteomic data in the translation of in vitro observations to associated clinical outcomes

A. Rostami-Hodjegan, B. Achour, S. Neuhoff, 2021, Drug Discovery Today: Technologies.

Intestinal P‐gp and Putative Hepatic OATP1B Induction: International Transporter Consortium Perspective on Drug Development Implications

Y. Sugiyama, K. Brouwer, X. Chu, 2020, Clinical pharmacology and therapeutics.

In Vitro–In Vivo Extrapolation Scaling Factors for Intestinal P-Glycoprotein and Breast Cancer Resistance Protein: Part I: A Cross-Laboratory Comparison of Transporter-Protein Abundances and Relative Expression Factors in Human Intestine and Caco-2 Cells

G. Warhurst, A. Rostami-Hodjegan, B. Achour, 2016, Drug Metabolism and Disposition.

Mass spectrometry‐based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin

N. Couto, A. Rostami-Hodjegan, B. Achour, 2020, FEBS letters.

Prediction of CYP‐mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator

Kuan-Fu Chen, K. Rowland Yeo, S. Neuhoff, 2022, CPT: pharmacometrics & systems pharmacology.

Population-Based Mechanistic Prediction of Oral Drug Absorption

Sebastian Polak, Masoud Jamei, Amin Rostami-Hodjegan, 2009, The AAPS Journal.

Guide to development of compound files for PBPK modeling in the Simcyp population‐based simulator

S. Neuhoff, I. Gardner, Mian Zhang, 2022, CPT: pharmacometrics & systems pharmacology.

Prediction of the in vivo behaviour of modified release formulations of metoprolol from in vitro dissolution profiles using the ADAM model (Simcyp V8)

M. Jamei, S. Polak, G. Tucker, 2008 .

Metformin and cimetidine: Physiologically based pharmacokinetic modelling to investigate transporter mediated drug-drug interactions.

K Rowland-Yeo, M Jamei, L Almond, 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites.

T. Andersson, C. Regårdh, P. Langguth, 2000, International journal of clinical pharmacology and therapeutics.

Was 4β‐hydroxycholesterol ever going to be a useful marker of CYP3A4 activity?

G. Tucker, S. Neuhoff, 2018, British journal of clinical pharmacology.

Risk–Benefit Assessment of Ethinylestradiol Using a Physiologically Based Pharmacokinetic Modeling Approach

K. Rowland Yeo, S. Neuhoff, I. Gardner, 2018, Clinical pharmacology and therapeutics.

DMD058446 1766..1772

G. Warhurst, A. Rostami-Hodjegan, S. Neuhoff, 2014 .

Caco-2 permeability of weakly basic drugs predicted with the double-sink PAMPA pKa(flux) method.

P. Artursson, L. Lazorova, A. Avdeef, 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Development of a physiologically based pharmacokinetic model to predict the effects of flavin‐containing monooxygenase 3 (FMO3) polymorphisms on itopride exposure

Diansong Zhou, S. Neuhoff, N. Al-Huniti, 2017, Biopharmaceutics & drug disposition.

Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective

Y. Sugiyama, K. Brouwer, X. Chu, 2022, Clinical pharmacology and therapeutics.

Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective

X. Chu, A. Galetin, M. Varma, 2022, Clinical pharmacology and therapeutics.

Regulation of Drug Transport Proteins—From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium

K. Brouwer, R. Evers, Shuiying Hu, 2022, Clinical pharmacology and therapeutics.

Food constituent– and herb–drug interactions in oncology: Influence of quantitative modelling on Drug labelling

S. Neuhoff, V. Pilla Reddy, Jo Heeseung, 2021, British journal of clinical pharmacology.

Performance Verification of CYP2C19 Enzyme Abundance Polymorphism Settings within the Simcyp Simulator v21

L. Gaohua, S. Neuhoff, Manting Chiang, 2022, Metabolites.

Non-specific binding of compounds in in vitro metabolism assays: a comparison of microsomal and hepatocyte binding in different species and an assessment of the accuracy of prediction models

M. Jamei, Yi Wang, S. Neuhoff, 2022, Xenobiotica; the fate of foreign compounds in biological systems.

Transporter Regulation in Critical Protective Barriers: Focus on Brain and Placenta

H. E. Meyer zu Schwabedissen, S. Neuhoff, M. Piquette-Miller, 2022, Pharmaceutics.

In vivo methods for drug absorption - comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects.

Talia Flanagan, Clive G. Wilson, Mai Anh Nguyen, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin.

Masoud Jamei, David B Turner, Amin Rostami-Hodjegan, 2013, Journal of pharmaceutical sciences.

Accounting for Transporters in Renal Clearance: Towards a Mechanistic Kidney Model (Mech KiM)

Lu Gaohua, Masoud Jamei, Amin Rostami-Hodjegan, 2013 .

PBPK models for evaluating membrane transporter mediated DDIs: Current capabilities, case studies, future opportunities and recommendations.

Yuichi Sugiyama, Ming Zheng, Jan Snoeys, 2019, Clinical pharmacology and therapeutics.

Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions

Sophie P. Chung, Shibing Deng, M. Jamei, 2013, Drug Metabolism and Disposition.

DMD050542 1367..1374

Sophie P. Chung, Shibing Deng, M. Jamei, 2013 .

Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P‐glycoprotein–cytochrome P450 3A4 dual substrates

S. Yamazaki, S. Neuhoff, V. Pilla Reddy, 2021, CPT: pharmacometrics & systems pharmacology.

Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.

W. Yue, K. Ding, S. Neuhoff, 2019, Journal of pharmaceutical sciences.

The Regional-Specific Relative and Absolute Expression of Gut Transporters in Adult Caucasians: A Meta-Analysis

Sibylle Neuhoff, S. Neuhoff, M. Harwood, 2019, Drug Metabolism and Disposition.

In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition

K. Ogungbenro, A. Rostami-Hodjegan, S. Neuhoff, 2022, The AAPS Journal.

Passive permeability and active transport models for the prediction of oral absorption

Per Artursson, Pär Matsson, S Neuhoff, 2007 .

Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics

J. Mochel, D. Pade, S. Neuhoff, 2021, The AAPS Journal.

Acamprosate Is a Substrate of the Human Organic Anion Transporter (OAT) 1 without OAT3 Inhibitory Properties: Implications for Renal Acamprosate Secretion and Drug–Drug Interactions

Christel A. S. Bergström, P. Artursson, C. Nielsen, 2020, Pharmaceutics.

Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer

J. Gribben, A. Boddy, S. Neuhoff, 2016, British journal of clinical pharmacology.

The permeation of acamprosate is predominantly caused by paracellular diffusion across Caco-2 cell monolayers: A paracellular modelling approach.

Christel A. S. Bergström, C. Nielsen, S. Neuhoff, 2019, Molecular pharmaceutics.

Caco-2 permeability of weakly basic drugs predicted with the Double-Sink PAMPA method

Per Artursson, Sibylle Neuhoff, Alex Avdeef, 2005 .

New approach methodologies (NAMs) for human-relevant biokinetics predictions: Meeting the paradigm shift in toxicology towards an animal-free chemical risk assessment.

Bas J Blaauboer, Alicia Paini, Paul Jennings, 2020, ALTEX.

Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: Estimating time varying CSF drug concentrations and their variability using in vitro data.

Lu Gaohua, Amin Rostami-Hodjegan, Masoud Jamei, 2016, Drug metabolism and pharmacokinetics.

More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter‐Mediated Clearances

Khaled Abduljalil, Sibylle Neuhoff, S. Neuhoff, 2016, Journal of clinical pharmacology.

Assessing OATP1B1- and OATP1B3-mediated drug-drug interaction potential of vemurafenib using R-value and physiologically based pharmacokinetic models.

W. Yue, K. Ding, S. Neuhoff, 2020, Journal of pharmaceutical sciences.

Pretreatment With Rifampicin and Tyrosine Kinase Inhibitor Dasatinib Potentiates the Inhibitory Effects Toward OATP1B1- and OATP1B3-Mediated Transport.

W. Yue, K. Ding, S. Neuhoff, 2017, Journal of pharmaceutical sciences.

Refined in vitro Models for Prediction of Intestinal Drug Transport : Role of pH and Extracellular Additives in the Caco-2 Cell Model

S. Neuhoff, 2005 .

pH-Dependent Bidirectional Transport of Weakly Basic Drugs Across Caco-2 Monolayers: Implications for Drug–Drug Interactions

Ismael Zamora, Per Artursson, Sibylle Neuhoff, 2003, Pharmaceutical Research.

Lost in Centrifugation: Accounting for Transporter Protein Losses in Quantitative Targeted Absolute Proteomics

G. Warhurst, A. Rostami-Hodjegan, S. Neuhoff, 2014, Drug Metabolism and Disposition.

Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions”

G. Tucker, S. Neuhoff, 2013, Pharmaceutical Research.

Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model.

A Rostami-Hodjegan, M Jamei, M. Jamei, 2010, Current drug metabolism.

In Vitro–In Vivo Extrapolation Scaling Factors for Intestinal P-glycoprotein and Breast Cancer Resistance Protein: Part II. The Impact of Cross-Laboratory Variations of Intestinal Transporter Relative Expression Factors on Predicted Drug Disposition

Amin Rostami-Hodjegan, Gordon Carlson, Brahim Achour, 2016, Drug Metabolism and Disposition.

Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs

M. Jamei, S. Neuhoff, R. Rose, 2017, The AAPS Journal.

Physiologically‐Based Pharmacokinetic Model of Morphine and Morphine‐3‐Glucuronide in Nonalcoholic Steatohepatitis

K. Brouwer, S. Neuhoff, Noora Sjöstedt, 2020, Clinical pharmacology and therapeutics.

PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants

A. Vinks, David Hahn, S. Neuhoff, 2018, CPT: pharmacometrics & systems pharmacology.

Interlaboratory Variability in the Madin–Darby Canine Kidney Cell Proteome

X. Chu, J. Wiśniewski, S. Neuhoff, 2023, Molecular pharmaceutics.

Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH)

K. Brouwer, J. Beaudoin, S. Siler, 2022, Clinical pharmacology and therapeutics.

Impact of Extracellular Protein Binding on Passive and Active Drug Transport Across Caco-2 Cells

Ismael Zamora, Per Artursson, Sibylle Neuhoff, 2005, Pharmaceutical Research.

Clive G. Wilson, A. Peer, H. Lennernäs, 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions”

G. Tucker, S. Neuhoff, 2013, Pharmaceutical Research.

Advantages and disadvantages of using bovine serum albumin and/or Cremophor EL as extracellular additives during transport studies of lipophilic compounds across Caco-2 monolayers

P. Artursson, A. Ungell, S. Neuhoff, 2007 .

Alterations in zonal distribution and plasma membrane localization of hepatocyte bile acid transporters in patients with NAFLD

P. Honkakoski, S. Neuhoff, M. Abdelmalek, 2024, Hepatology communications.